Comparison
Trevogrumab vs Follistatin-344
Systemic muscle-sparing vs. site-specific myostatin inhibition — actual trial data versus experimental niche.
Trevogrumab
Anti-Myostatin Monoclonal Antibody
Follistatin-344
Myostatin / Activin Inhibitor
Effectiveness Profile
At a Glance
| Trevogrumab | Follistatin-344 | |
|---|---|---|
| Type | Other | Other |
| Legal status | Research | Research |
| Half-life | ~2–4 weeks (IgG4 class estimate) | ~1 hour (circulating); longer tissue residence at depot site |
| Preferred route | IV | SubQ (site-specific over target muscle) |
| Dose frequency | custom | once-daily |
| Beginner dose | 200–200 mg | 50–100 mcg |
| Intermediate dose | 400–400 mg | 100–200 mcg |
| Advanced dose | 400–400 mg | 300–500 mcg |
| Cycle length | 26–52 wks | 2–4 wks |
| Bioavailability | 100% | — |
| Time to peak | 2h | 0.25h |
| Active duration | 672h | 24h |
| Storage | 2–8°C refrigerated; do not freeze; protect from light | Lyophilized: -20°C long-term, 2–8°C short-term. Reconstituted: 2–8°C refrigerated, use within 2–3 weeks. |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Trevogrumab wins for legitimate systemic muscle-sparing with modern weight-loss agents (especially GLP-1s), documented efficacy in human-grade trials, a clean selectivity profile with minimal off-target pathway impact, and no direct risk of local tissue or vision complications.
Follistatin-344 wins for site-targeted hypertrophy on lagging muscles, direct tissue-level application, broader inhibition (myostatin, activin, TGF-β ligands), off-label blendability in research stacks, and practical accessibility from peptide sources, despite a lack of human data for physique outcomes.
Pick A or B?
Pick Trevogrumab if:
- The protocol is GLP-1–based (semaglutide/tirzepatide) and requires preservation of lean mass during aggressive body recomposition.
- Documented, peer-reviewed efficacy data is a primary driver in compound selection.
- Avoidance of off-target pathway inhibition is critical (clean avoidance of activin A/GDF11 actions).
- Sourcing from legitimate clinical trials or collaborations is possible.
- Seeking a system-wide muscle-sparing adjunct, not localized muscle growth.
Pick Follistatin-344 if:
- The primary goal is hypertrophy focused on a stubborn or lagging muscle group (site-specific application).
- Research requires a broad-spectrum ligand trap (myostatin, activin, TGF-β trapping) not achievable with antibody-only approaches.
- Rapid access to experimental peptides is needed (peptide-market sourcing, not limited by clinical pipeline).
- Willingness to operate in an under-documented, "grey area" research domain.
- Stacking with IGF-1 LR3, MGF, or GH/GHRPs for synergistic hypertrophy at the tissue level is planned.
Where to Buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Trevogrumab· Buy Trevogrumab 1mg (1 vial) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Trevogrumab
- Follistatin-344· Buy Follistatin-344 1 mg (1 vial) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Follistatin-344